182 related articles for article (PubMed ID: 35411446)
21. Five-year trends of bone scan and prostate-specific membrane antigen positron emission tomography utilization in prostate cancer: A retrospective review in a private centre.
Haran C; McBean R; Parsons R; Wong D
J Med Imaging Radiat Oncol; 2019 Aug; 63(4):495-499. PubMed ID: 30972933
[TBL] [Abstract][Full Text] [Related]
22. Effect of
Metser U; Zukotynski K; Mak V; Langer D; MacCrostie P; Finelli A; Kapoor A; Chin J; Lavallée L; Klotz LH; Hagerty M; Hildebrand C; Bauman G
Radiology; 2022 May; 303(2):414-422. PubMed ID: 35076300
[TBL] [Abstract][Full Text] [Related]
23. The Diagnostic Performance of 18F-PSMA-1007 PET/CT in Prostate Cancer Patients with Early Recurrence after Definitive Therapy with a PSA <10 ng/ml.
Lengana T; Lawal I; Janse Van Rensburg C; Mokoala K; Moshokoa E; Mazibuko S; Van de Wiele C; Maes A; Vorster M; Sathekge MM
Nuklearmedizin; 2022 Apr; 61(2):120-129. PubMed ID: 35421900
[TBL] [Abstract][Full Text] [Related]
24. The use of
Meredith G; Wong D; Yaxley J; Coughlin G; Thompson L; Kua B; Gianduzzo T
BJU Int; 2016 Oct; 118 Suppl 3():49-55. PubMed ID: 27659411
[TBL] [Abstract][Full Text] [Related]
25. The role of 68Ga-PSMA PET/CT scan in biochemical recurrence after primary treatment for prostate cancer: a systematic review of the literature.
Eissa A; Elsherbiny A; Coelho RF; Rassweiler J; Davis JW; Porpiglia F; Patel VR; Prandini N; Micali S; Sighinolfi MC; Puliatti S; Rocco B; Bianchi G
Minerva Urol Nefrol; 2018 Oct; 70(5):462-478. PubMed ID: 29664244
[TBL] [Abstract][Full Text] [Related]
26. [Diagnostic performance of 68GA-PSMA PET/CTin patients with prostate cancer].
Veliev EI; Tomilov AA; Goncharuk DA; Bogdanov AB; Golubtsova EN
Urologiia; 2018 Jul; (3):105-110. PubMed ID: 30035428
[TBL] [Abstract][Full Text] [Related]
27. Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy.
Morigi JJ; Stricker PD; van Leeuwen PJ; Tang R; Ho B; Nguyen Q; Hruby G; Fogarty G; Jagavkar R; Kneebone A; Hickey A; Fanti S; Tarlinton L; Emmett L
J Nucl Med; 2015 Aug; 56(8):1185-90. PubMed ID: 26112024
[TBL] [Abstract][Full Text] [Related]
28. Impact of piflufolastat F-18 PSMA PET imaging on clinical decision-making in prostate cancer across disease states: A retrospective review.
Arafa AT; Jain A; Skrobanek P; Humphrey B; Froelich JW; Antonarakis ES
Prostate; 2023 Jun; 83(9):863-870. PubMed ID: 36999911
[TBL] [Abstract][Full Text] [Related]
29. Diagnostic Performance and Clinical Impact of
Cerci JJ; Fanti S; Lobato EE; Kunikowska J; Alonso O; Medina S; Novruzov F; Lengana T; Granados C; Kumar R; Rangarajan V; Al-Ibraheem A; Hourani M; Ali NS; Ahmad A; Keidar Z; Küçük O; Elboga U; Bogoni M; Paez D
J Nucl Med; 2022 Feb; 63(2):240-247. PubMed ID: 34215674
[TBL] [Abstract][Full Text] [Related]
30. The use of
Raveenthiran S; Yaxley J; Gianduzzo T; Kua B; McEwan L; Wong D; Tsang G; MacKean J
Prostate Cancer Prostatic Dis; 2019 Sep; 22(3):385-390. PubMed ID: 31363165
[TBL] [Abstract][Full Text] [Related]
31. The Impact of
Roach PJ; Francis R; Emmett L; Hsiao E; Kneebone A; Hruby G; Eade T; Nguyen QA; Thompson BD; Cusick T; McCarthy M; Tang C; Ho B; Stricker PD; Scott AM
J Nucl Med; 2018 Jan; 59(1):82-88. PubMed ID: 28646014
[No Abstract] [Full Text] [Related]
32. Detection Efficacy of Hybrid
Einspieler I; Rauscher I; Düwel C; Krönke M; Rischpler C; Habl G; Dewes S; Ott A; Wester HJ; Schwaiger M; Maurer T; Eiber M
J Nucl Med; 2017 Jul; 58(7):1081-1087. PubMed ID: 28209912
[TBL] [Abstract][Full Text] [Related]
33. Diagnostic accuracy of
Liu X; Wang Q; Zhang B; Jiang T; Zeng W
Hell J Nucl Med; 2022; 25(1):88-102. PubMed ID: 35388806
[TBL] [Abstract][Full Text] [Related]
34. Clinical impact of PSMA-based
Mena E; Lindenberg ML; Shih JH; Adler S; Harmon S; Bergvall E; Citrin D; Dahut W; Ton AT; McKinney Y; Weaver J; Eclarinal P; Forest A; Afari G; Bhattacharyya S; Mease RC; Merino MJ; Pinto P; Wood BJ; Jacobs P; Pomper MG; Choyke PL; Turkbey B
Eur J Nucl Med Mol Imaging; 2018 Jan; 45(1):4-11. PubMed ID: 28894899
[TBL] [Abstract][Full Text] [Related]
35. 68Ga-PSMA-11 PET-CT study in prostate cancer patients with biochemical recurrence and non-contributive 18F-Choline PET-CT: Impact on therapeutic decision-making and biomarker changes.
Barbaud M; Frindel M; Ferrer L; Le Thiec M; Rusu D; Rauscher A; Maucherat B; Baumgartner P; Fleury V; Colombié M; Thierry-Morel A; Kraeber-Bodéré F; Campion L; Rousseau C
Prostate; 2019 Apr; 79(5):454-461. PubMed ID: 30549066
[TBL] [Abstract][Full Text] [Related]
36. Pathological predictors of
Perry E; Talwar A; Taubman K; Ng M; Wong LM; Sutherland TR
BJU Int; 2022 Jun; 130 Suppl 1(Suppl 1):28-36. PubMed ID: 35768883
[TBL] [Abstract][Full Text] [Related]
37. [
Dietlein F; Mueller P; Kobe C; Endepols H; Hohberg M; Zlatopolskiy BD; Krapf P; Heidenreich A; Neumaier B; Drzezga A; Dietlein M
Mol Imaging Biol; 2021 Apr; 23(2):277-286. PubMed ID: 33006028
[TBL] [Abstract][Full Text] [Related]
38. Oligometastatic disease in biochemical recurrence of prostate cancer: Prevalence on PSMA PET/CT and consecutive metastasis-directed therapy - Experience at a tertiary referral center.
Müller PJ; Dietlein M; Kobe C; Heidenreich A; Drzezga A
Nuklearmedizin; 2022 Aug; 61(4):314-324. PubMed ID: 35388442
[TBL] [Abstract][Full Text] [Related]
39. Role of 68Ga and 18F PSMA PET/CT and PET/MRI in biochemical recurrence of prostate cancer: a systematic review of prospective studies.
Mazrani W; Cook GJR; Bomanji J
Nucl Med Commun; 2022 Jun; 43(6):631-637. PubMed ID: 35438666
[TBL] [Abstract][Full Text] [Related]
40.
Davies A; Foo M; Gan CL; Kourambas J; Redgrave N; Donnellan S; Appu S; Williams S; Coleman A; Segelov E; Bradley J; Soo G; Ramdave S; Kwan EM; Azad AA
Asia Pac J Clin Oncol; 2022 Oct; 18(5):e204-e210. PubMed ID: 34161628
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
